Maria Rita Gaiser

Maria Rita Gaiser

Auto-generated profile, based on publicly available information

Maria Rita Gaiser

Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim der Universität Heidelberg

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
MGMaria Rita Gaiser
Maria Rita Gaiser
KDKenneth Daily
Kenneth Daily
JHJochen Hoffmann
Jochen Hoffmann
MBMaik Brune
Maik Brune
AEAlexander Enk
Alexander Enk
IBIsaac Brownell
Isaac Brownell
Evaluating blood levels of neuron specific enolase, chromogranin A, and circulating tumor cells as Merkel cell carcinoma biomarkers

8 February 2018 in OncoImmunology
Verified
Journal Article
Open access
MGMaria Rita Gaiser
Maria Rita Gaiser
CWCleo-Aron Weis
Cleo-Aron Weis
TGTimo Gaiser
Timo Gaiser
HJHong Jiang
Hong Jiang
KBKristina Buder-Bakhaya
Kristina Buder-Bakhaya
IBIsaac Brownell
Isaac Brownell
Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer that responds to PD-1/PD-L1 immune checkpoint inhibitors. CD200 is another checkpoint modulator whose receptor is found on tumor-promoting myeloid cells, including M2 macrophages. We found high CD200 mRNA expression in MCC tumors, and CD200 immunostaining was demonstrated on 95.5% of MCC tumors. CD200R-expressing myeloid cells were present in the MCC tumor microenvironment. MCC-associated macrophages had a higher average CD163:CD68 staining ratio (2.67) than controls (1.13), indicating an immunosuppressive M2 phenotype. Accordingly, MCC tumors contained increased densities of FOXP3+ regulatory T-cells. Intravenous administration of blocking anti-CD200 antibody to MCC xenograft mice revealed specific targeting of drug to tumor. In conclusion, MCC are highly CD200 positive and associated with immunosuppressive M2 macrophages and regulatory T-cells. As anti-CD200 antibody effectively targets CD200 on MCC tumor cells in vivo, this treatment may provide a novel immunotherapy for MCC independent of PD-1/PD-L1 blockade.

7 March 2018 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Closed access
PDF file
MGMaria Rita Gaiser
Maria Rita Gaiser
NBNikolas von Bubnoff
Nikolas von Bubnoff
Christoffer GebhardtChristoffer Gebhardt
Christoffer Gebhardt
Jochen UtikalJochen Utikal
Jochen Utikal

1 January 2015 in Journal of Dermatological Science
Verified
Journal Article
Closed access
MGMaria R. Gaiser
Maria R. Gaiser
STSonja Textor
Sonja Textor
TSTilo Senger
Tilo Senger
LSLysann Schädlich
Lysann Schädlich
TWTim Waterboer
Tim Waterboer
ALAnke S. Lonsdorf
Anke S. Lonsdorf

15 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
SVSerena Vilasi
Serena Vilasi
JNJannett Nguyen
Jannett Nguyen
CWCatherine J. Wang
Catherine J. Wang
LMLingling Miao
Lingling Miao
KDKenneth Daily
Kenneth Daily
IBIsaac Brownell
Isaac Brownell
Merkel cell carcinoma (MCC) and small cell lung cancer (SCLC) can be histologically similar. Immunohistochemistry (IHC) for cytokeratin 20 (CK20) and thyroid transcription factor 1 (TTF-1) are commonly used to differentiate MCC from SCLC; however, these markers have limited sensitivity and specificity. To identify new diagnostic markers, we performed differential gene expression analysis on transcriptome data from MCC and SCLC tumors. Candidate markers included atonal BHLH transcription factor 1 (ATOH1) and transcription factor AP-2β (TFAP2B) for MCC, as well as carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) for SCLC. Immunostaining for CK20, TTF-1, and new candidate markers was performed on 43 MCC and 59 SCLC samples. All three MCC markers were sensitive and specific, with CK20 and ATOH1 staining 43/43 (100%) MCC and 0/59 (0%) SCLC cases and TFAP2B staining 40/43 (93%) MCC and 0/59 (0%) SCLC cases. TTF-1 stained 47/59 (80%) SCLC and 1/43 (2%) MCC cases. CEACAM6 stained 49/59 (83%) SCLC and 0/43 (0%) MCC cases. Combining CEACAM6 and TTF-1 increased SCLC detection sensitivity to 93% and specificity to 98%. These data suggest that ATOH1, TFAP2B, and CEACAM6 should be explored as markers to differentiate MCC and SCLC.

1 December 2018 in Annals of Oncology
Verified
Journal Article
Closed access
MGM.R. Gaiser
M.R. Gaiser
SLS. Lorenzen
S. Lorenzen
KMK. Merx
K. Merx
JTJ. Trojan
J. Trojan
JOJ. Ocvirk
J. Ocvirk
RHR.-D. Hofheinz
R.-D. Hofheinz